EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Genome-Wide Association Study in Psoriasis Patients Reveals Variants Associated with Response to Treatment with Interleukin-17A Pathway Inhibitors

Dimitra Ioakeimidou, Efterpi Zafiriou, Themistoklis Giannoulis iD, Olga Kouvarou, Kalliopi Gerogianni, Dimitrios P Bogdanos iD, Theologia Sarafidou, Kalliopi Liadaki iD

Genes · 13.10.2025 · 16 (10) · 1187

DOI: 10.3390/genes16101187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, online erschienen am 13.10.2025. Verfasst von Dimitra Ioakeimidou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Psoriasis is currently treated with biologics targeting the IL-17A signaling, which plays a major role in immune response and keratinocyte hyperproliferation. These include inhibitors of IL-17A and/or its heterodimer with IL-17F (Secukinumab, Ixekinumab and Bimekizumab) and the receptor IL17-RA (Brodalumab). Although these drugs are safe and highly effective, there is significant variability in response among patients. This can be partly attributed to the patients’ genetic background, thus pointing to the need to identify pharmacogenetic markers for treatment response.

Methods

The study involved 88 Greek patients who were treated with inhibitors of the IL-17A signaling for at least 6 months. Patients were classified as responders and non-responders according to the change in Psoriasis Area Severity Index. A total of 730,000 variants were genotyped and analyzed for association with the 3-month and 6-month responses to treatment.

Results

The analysis identified 21 variants which were associated with the response, showing statistical significance after Bonferroni correction. These include variants located in protein coding genes (TP63, NRG1, SCN8A, TAF9, TMEM9, SMIM36, SYT14, BPIFC, SEZ6L2, PCARE), as well as intergenic and long non-coding RNA intronic variants. The functional significance of the variants was assessed using in silico analysis and for several variants, a link with immune processes was proposed. Notably, rs11649499 status, which was associated with complete clinical remission at 3 months, may influence key lipid mediators involved in psoriasis.

Conclusions

This GWAS identified novel variants that could be utilized upon validation in larger populations as predictive markers regarding patient response to drugs targeting the IL-17A pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisInterleukin-17HumansMaleFemaleMiddle AgedGenome-Wide Association StudyAdultAntibodies, Monoclonal, HumanizedPolymorphism, Single NucleotideSignal TransductionAgedDermatologic AgentsTreatment Outcome

Stichwörter der Autor:innen

Interleukin 17 inhibitorsInterleukin 17 receptor inhibitorgenome-wide association studypsoriasis

Substanzen

Interleukin-17IL17A protein, humanAntibodies, Monoclonal, HumanizedbrodalumabixekizumabDermatologic Agentssecukinumabbimekizumab

Autor:innen und Institutionen

  • Department of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece.
  • Department of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece.
  • Department of Animal Science, University of Thessaly, Gaiopolis, 41334 Larissa, Greece.
  • Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41500 Larissa, Greece.

ORCID-Profile: Themistoklis Giannoulis, Dimitrios P Bogdanos, Kalliopi Liadaki

Zitieren

APA

Ioakeimidou, D., Zafiriou, E., Giannoulis, T., Kouvarou, O., Gerogianni, K., Bogdanos, D. P., Sarafidou, T., & Liadaki, K. (2025). A Genome-Wide Association Study in Psoriasis Patients Reveals Variants Associated with Response to Treatment with Interleukin-17A Pathway Inhibitors. Genes, 16(10), 1187. https://doi.org/10.3390/genes16101187

Vancouver

Ioakeimidou D, Zafiriou E, Giannoulis T, Kouvarou O, Gerogianni K, Bogdanos DP, et al. A Genome-Wide Association Study in Psoriasis Patients Reveals Variants Associated with Response to Treatment with Interleukin-17A Pathway Inhibitors. Genes. 2025;16(10):1187. doi:10.3390/genes16101187

BibTeX
@article{Ioakeimidou2025,
  author = {Ioakeimidou, Dimitra and Zafiriou, Efterpi and Giannoulis, Themistoklis and Kouvarou, Olga and Gerogianni, Kalliopi and Bogdanos, Dimitrios P and Sarafidou, Theologia and Liadaki, Kalliopi},
  title = {A Genome-Wide Association Study in Psoriasis Patients Reveals Variants Associated with Response to Treatment with Interleukin-17A Pathway Inhibitors},
  journal = {Genes},
  year = {2025},
  volume = {16},
  number = {10},
  pages = {1187},
  doi = {10.3390/genes16101187}
}
Kostenlos starten →